MorphoSys Press Release: MorphoSys Successfully Concludes Therapeutic Antibody Project

09-Aug-2005

MorphoSys AG announced the successful conclusion of a first therapeutic antibody program with Novartis. MorphoSys generated numerous fully human antibodies fulfilling previously defined success criteria against a cancer disease-related target molecule from Novartis, and thus achieved the first performance-related milestone in the cooperation. The amount of the associated milestone payment made to MorphoSys was not disclosed. The project work commenced in September 2004 and was completed within 11 months.

In May 2004, MorphoSys and Novartis forged a strategic antibody alliance to jointly develop new antibody-based therapeutic substances against a range of illnesses for which the current treatment is inadequate. As part of the cooperation, Novartis decided to acquire an equity stake in MorphoSys worth around EUR 9 million.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous